| CereVasc, Inc. Announces Publication of a Multi-Center Study Evaluating the eShunt® System in the Treatment of Patients with NPH 95% of Participants Demonstrated Clinical Improvement with No Device-Related Serious Adverse Events Through 90-Day Follow-Up BOSTON, February 24, 2026 – CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, today announced results […] The post CereVasc, Inc. Announces Publication of a Multi-Center Study Evaluating the eShunt® System in the Treatment of Patients with NPH appeared first on CereVasc |
Neurologic |
